Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	1.58B +534.1%
Revenue (ttm)	123.67M +63.5%
Net Income	-38.63M
EPS	-0.46
Shares Out	80.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,186
Open	20.23
Previous Close	20.17
Day's Range	19.44 - 20.45
52-Week Range	3.51 - 25.77
Beta	1.64
Analysts	Strong Buy
Price Target	32.00 (+61.7%)
Earnings Date	May 8, 2026

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE
• Website: https://www.monterosatx.com

Financial Performance

In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 61.70% from the latest price.

Price Target

$32.0

(61.70% upside)

Analyst Consensus: Strong Buy